Relevance of lipopolysaccharide levels in HIV-associated neurocognitive impairment: the Neuradapt study

被引:0
|
作者
Matteo Vassallo
Brigitte Dunais
Jacques Durant
Helene Carsenti-Dellamonica
Alexandra Harvey-Langton
Jacqueline Cottalorda
Michel Ticchioni
Muriel Laffon
Christine Lebrun-Frenay
Pierre Dellamonica
Christian Pradier
机构
[1] University of Nice,Department of Infectious Diseases, L’Archet Hospital
[2] University of Nice,Department of Public Health, L’Archet Hospital
[3] University of Nice,Virology Laboratory Unit, L’Archet Hospital
[4] University of Nice,Immunology Laboratory Unit, L’Archet Hospital
[5] University of Nice,Department of Neurology, Pasteur Hospital
来源
Journal of NeuroVirology | 2013年 / 19卷
关键词
Lipopolysaccharide; HIV-associated neurocognitive disorders; Antiretroviral therapy;
D O I
暂无
中图分类号
学科分类号
摘要
Contributory factors to HIV-associated neurocognitive disorders (HAND) have been shown to include age, co-morbid infections, medication toxicity, virological, genetic and vascular mechanisms, as well as microbial translocation of lipopolysaccharide (LPS), which is suspected to trigger monocyte activation and increase trafficking of infected cells into the brain. In this study, our aim was to assess the degree of neurocognitive impairment in a group of randomly selected HIV-infected patients and investigate potential risk factors, including LPS plasma levels. Furthermore, we evaluated the relevance of LPS as a potential marker for screening patients with mild neurocognitive impairment. LPS plasma levels were compared among patients with HAND and those with no HAND. As LPS has also been shown to be elevated in hepatitis C co-infection, the analysis was stratified according to the presence or not of hepatitis C virus (HCV) co-infection. Differences between groups were evaluated using chi-square tests and Kruskal–Wallis non-parametric tests. Stepwise logistic regression was performed to identify independent risk factors for HAND in the subgroups of HCV-positive and negative patients. A p value <0.05 was considered significant. Analyses were conducted using SPSS® software. From December 2007 to July 2009, 179 patients were tested (mean age 44, 73 % male, 87 % on treatment, 30 % HCV co-infected, median CD4 504/ml and 67 % with viral load below 40 copies/ml). HAND was identified in 40/179 patients (22 %), the majority displaying asymptomatic neurocognitive impairment or mild neurocognitive disorder. Univariate analysis showed that age, illicit drug use, hepatitis C co-infection, prior AIDS-defining events, CD4/CD8 ratio and LPS plasma levels were significantly associated with HAND. The median LPS level was 98.2 pg/ml in the non-HAND group versus 116.1 pg/ml in the HAND group (p < 0.014). No differences were found in LPS values between subgroups of impairment. There was a clear association between LPS levels and HAND in the HCV-positive group (p = 0.036), while there was none in the HCV-negative group (p = 0.502). No difference in degree of hepatic fibrosis was found between the HAND and non-HAND groups. In conclusion, LPS levels were associated with HAND in the HCV-positive group, while, in the HCV-negative group, age and pro-viral DNA were the only variables independently associated with HAND. There was no difference in degree of liver disease as predicted by score of fibrosis between HAND and non-HAND groups. The role of HCV co-infection and higher LPS levels in the pathogenesis of HAND in patients with viral suppression on treatment requires further investigation.
引用
收藏
页码:376 / 382
页数:6
相关论文
共 50 条
  • [41] Plasma Cytokine Biomarker Cutoff Values for HIV-Associated Neurocognitive Impairment in Adults
    Ruhanya, Vurayai
    Jacobs, Graeme B.
    Paul, Robert H.
    Joska, John A.
    Seedat, Soraya
    Nyandoro, George
    Engelbrecht, Susan
    Glashoff, Richard H.
    VIRAL IMMUNOLOGY, 2021, 34 (10) : 689 - 696
  • [42] Distinguishing Amnestic Mild Cognitive Impairment From HIV-Associated Neurocognitive Disorders
    Sundermann, Erin E.
    Bondi, Mark W.
    Campbell, Laura M.
    Gouaux, Ben
    Moore, Raeanne C.
    Soontornniyomkij, Virawudh
    Moore, David J.
    JOURNAL OF INFECTIOUS DISEASES, 2021, 224 (03): : 435 - 442
  • [43] Early prediction of putamen imaging features in HIV-associated neurocognitive impairment syndrome
    Yu Qi
    Man Xu
    Wei Wang
    Yuan-Yuan Wang
    Jiao-Jiao Liu
    Hai-Xia Ren
    Ming-Ming Liu
    Rui-Li Li
    Hong-Jun Li
    BMC Neurology, 21
  • [44] Early prediction of putamen imaging features in HIV-associated neurocognitive impairment syndrome
    Qi, Yu
    Xu, Man
    Wang, Wei
    Wang, Yuan-Yuan
    Liu, Jiao-Jiao
    Ren, Hai-Xia
    Liu, Ming-Ming
    Li, Rui-Li
    Li, Hong-Jun
    BMC NEUROLOGY, 2021, 21 (01)
  • [45] Elevated CSF Neurofilament H levels in HIV-associated neurocognitive disorder
    Anderson, Caroline F.
    Sacktor, Ned
    McArthur, Justin C.
    Nath, Avindra
    JOURNAL OF NEUROVIROLOGY, 2010, 16 : 5 - 5
  • [46] HIV-Associated Neurocognitive Disorders (HAND)
    Elbirt, Daniel
    Mahlab-Guri, Keren
    Bezalel-Rosenberg, Shira
    Gill, Harpreet
    Attali, Malka
    Asher, Ilan
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2015, 17 (01): : 54 - 59
  • [47] The Metamorphosis of HIV-Associated Neurocognitive Disorders
    Jennifer Lyons
    Current Infectious Disease Reports, 2013, 15 : 451 - 452
  • [48] Drugs of Abuse, Dopamine, and HIV-Associated Neurocognitive Disorders/HIV-Associated Dementia
    Vishnudutt Purohit
    Rao Rapaka
    David Shurtleff
    Molecular Neurobiology, 2011, 44 : 102 - 110
  • [49] Update on HIV-Associated Neurocognitive Disorders
    Alfahad, Tariq B.
    Nath, Avindra
    CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2013, 13 (10)
  • [50] The Metamorphosis of HIV-Associated Neurocognitive Disorders
    Lyons, Jennifer
    CURRENT INFECTIOUS DISEASE REPORTS, 2013, 15 (06) : 451 - 452